DNA Marker Predicts Platinum Drug Response in Breast, Ovarian Cancer
Thursday, March 22, 2012 - 10:00
in Health & Medicine
Brigham and Women's Hospital and Dana-Farber Cancer Institute researchers have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers might respond to platinum-based chemotherapies.